Everything below concerns clinical development. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Setipiprant (INN; developmental code names ACT-129968, KYTH-105) is an investigational drug developed for the treatment of asthma and scalp hair loss. It was originally developed by Actelion and acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). The drug is being developed as a novel treatment for male pattern baldness by Allergan.
Second Cup agreed to transform some of its western Canada locations into recreational cannabis dispensaries, with no cannabis-related products to be sold at its cafés. The company stated that this alliance would allow it to leverage its real estate assets to drive value for the franchisees without affecting plans for new product innovation and opening new cafés across Canada. In August 2018, the company was already considering which of its locations in Ontario might be suitable as cannabis retail stores as an alternative to their current use, in conjunction with National Access Cannabis. On November 8, 2019, Second Cup announced plans to change its name to Aegis Brands Inc. (TSX: AEG), pending stockholder approval the following year. The company was scheduled to open two cannabis stores in Calgary in early 2020 and planned expansion into Ontario. On December 5, 2019, Aegis Brands announced its acquisition of Ottawa-based coffeehouse chain Bridgehead Coffee for $11 million. In February 2021, Aegis Brands agreed to sell Second Cup to Quebec-based Foodtastic Inc. for an undisclosed sale price that included $14 million in cash. Foodtastic chief executive Peter Mammas said that the company intended to expand the brand to 300 locations by 2025, from the existing store count of 190. In May 2025, Second Cup's international division filed for creditor protection under the Companies' Creditors Arrangement Act in Canada. This comes after the company was unable to pay nearly $10 million to its creditors.
After 1945, many of the films of the immediate post-war period can be characterised as Trümmerfilm (rubble film). East German film was dominated by the state-owned film studio DEFA, while the dominant genre in West Germany was the Heimatfilm ("homeland film"). The Academy Award for Best Foreign Language Film ("Oscar") went to the German production The Tin Drum (Die Blechtrommel) in 1979, to Nowhere in Africa (Nirgendwo in Afrika) in 2002, and to The Lives of Others (Das Leben der Anderen) in 2007. Various Germans won an Oscar for their performances in films. The annual European Film Awards ceremony is held every other year in Berlin, home of the European Film Academy. The Berlin International Film Festival known as "Berlinale", awarding the "Golden Bear" and held annually since 1951, is one of the world's leading film festivals. The "Lolas" are annually awarded in Berlin, at the German Film Awards.
The largest and sole study employing bicalutamide, an industry-sponsored, phase II, multicenter, international, open-label, single-arm clinical trial known as the Bicalutamide and Anastrozole Treatment of Testotoxicosis (BATT) study, assessed the combination of 12.5 to 100 mg/day bicalutamide and 0.5 to 1 mg/day anastrozole over a period of 12 months in 14 young boys with FMPP. The mean age of the boys was 4 ± 2 years, with a range of 2 to 9 years of age. At baseline, the boys weighed 23 ± 6 kg (52 ± 12 lbs) on average, with a range 17 to 35 kg (37 to 77 lbs). Mean total levels of testosterone in the boys were 277 ± 208 ng/dL at baseline and increased to 523 ± 258 ng/dL at 6 months and 427 ± 243 ng/dL at 12 months. Mean total levels of estradiol in the boys were 3.8 pg/mL at baseline and were relatively unchanged at 6 and 12 months (2.5 pg/mL and 3.5 pg/mL, respectively). The dosage of bicalutamide was initiated at 12.5 mg/day and was then increased, with adjustment as necessary to maintain trough circulating (R)-bicalutamide concentrations within a target range of 5 to 15 μg/mL. This range is similar to (R)-bicalutamide levels achieved with approximately 30 to 100 mg/day bicalutamide in adult men with prostate cancer. The mean final dosage of bicalutamide in the boys at 12 months was 60 ± 29 mg/day, with 86% of the boys on either 50 or 100 mg/day bicalutamide. Levels of (R)-bicalutamide were proportional to dosage and did not appear to be related to the age or weight of the boys.
=== Retail sale of sauces === In the spring of 2020, Chick-fil-A test-trialed the sale of two of their dipping sauces at some supermarkets in Florida, with all profits earmarked for a scholarship fund for the company's store-level employees. The trial was considered successful, and distribution was expanded nationwide by 2021. Two more sauces were added in 2023. In October 2022, the company trialed expansion of the program to include its salad dressings in the Cincinnati metropolitan area and in parts of Tennessee, and expanded nationwide in spring 2023. In January 2025, Chick-fil-A announced plans to centralize its lemonade production by moving it from its restaurant locations to a single, automated facility in Santa Clarita, California. This new plant is capable of processing between 30 and 35 truckloads of lemons daily, with each truckload containing 50,000 pounds of lemons.
Sources: en.wikipedia.org
German literature can be traced back to the Middle Ages and the works of writers such as Walther von der Vogelweide and Wolfram von Eschenbach. Well-known German authors include Johann Wolfgang von Goethe, Friedrich Schiller, Gotthold Ephraim Lessing and Theodor Fontane. The collections of folk tales published by the Brothers Grimm popularised German folklore on an international level. The Grimms also gathered and codified regional variants of the German language, grounding their work in historical principles; their Deutsches Wörterbuch, or German Dictionary, sometimes called the Grimm dictionary, was begun in 1838 and the first volumes published in 1854. Influential authors of the 20th century include Gerhart Hauptmann, Thomas Mann, Hermann Hesse, Heinrich Böll, and Günter Grass. The German book market is the third-largest in the world, after the United States and China. The Frankfurt Book Fair is the most important in the world for international deals and trading, with a tradition spanning over 500 years. The Leipzig Book Fair also retains a major position in Europe.
== Long-lasting erections == Antiandrogens can considerably relieve and prevent priapism (potentially painful penile erections that last more than four hours) via direct blockade of penile ARs. In accordance, bicalutamide, at low dosages (50 mg every other day or as little as once or twice weekly), has been found in a series of case reports to completely resolve recurrent priapism in men without producing significant side effects, and is used for this indication off-label. In the reported cases, libido, rigid erections, the potential for sexual intercourse, orgasm, and subjective ejaculatory volume have all remained intact or unchanged, and gynecomastia has not developed when bicalutamide is administered at a total dosage of 25 mg/day or less. Some gynecomastia and breast tenderness developed in one patient treated with 50 mg/day, but significantly improved upon the dosage being halved. The observed tolerability profile of bicalutamide in these subjects has been regarded as significantly more favorable than that of GnRH analogues and estrogens (which are also used in the treatment of this condition). However, although successful and well tolerated, very few cases have been reported. Despite the apparent efficacy of bicalutamide for priapism, a small clinical study found that bicalutamide monotherapy at a dosage of 50 mg/day had no effect on nocturnal erections in men with prostate cancer.
=== Removal of additives === In 2011, food blogger and activist Vani Hari noted that Chick-fil-A sandwiches contained nearly 100 ingredients, including peanut oil preserved with tert-butylhydroquinone (TBHQ), made from butane. In October 2012, Chick-fil-A invited Hari to meet with company executives at its headquarters. In December 2013, Chick-fil-A said that it was removing high-fructose corn syrup and artificial dyes, and was testing a new peanut oil. Like other companies, Chick-fil-A does not publicly announce such changes unless already in the news, because it focuses on these ingredients.
=== Portuguese === Luso-American Financial - A Fraternal Benefit Society - Founded in 1868 as the Portuguese Protective and Benevolent Association of the City and County of San Francisco. Grand Council, most likely a state organization, was founded in 1872, and Supreme Council in 1921. Changed name to Benevolent Society of California in 1948. Women were admitted in 1945. Merged with the Uniao Portuguesa Continental do Estado da California (f.1917) in 1957 to become United National Life Insurance Society, later adopted its current name. Reincorporated in 1975. Luso-American Fraternal Federation founded in 1957 to administer fraternal aspect. Administers Luso-American Educational Foundation which grants scholarships to students interested in Portuguese history and culture. Headquarters in Oakland, lodges called "Subordinate lodges" which were present in California, Nevada, Massachusetts, Connecticut, and Rhode Island. In 1978 it had 14,000 members. In 1994 it was reported to have 15,000. Membership is open to Americans of Portuguese descent or birth. Society of the Holy Spirit of the State of California - Founded in Santa Clara, California, in 1895. Headquartered in Santa Clara. Lodges are called Subordinate Councils; the highest is known as the "Supreme Council" which holds a convention annually. Membership is open to all. 1979 membership 11,500, a slight increase since 1972. There is a ritual with provisions for questions and answers, hymns pledges, and passwords.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.